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Dendritic cells (DCs) are specialized antigen-
presenting cells and essential mediators of immunity 
and tolerance. Studies of immunology and disease 
have long focused on antigens and lymphocytes (B 
cells, T cells, NK cells) as the mediators of immune 
responses. However, accumulating evidence shows 
that dendritic cells provide vital links between 
antigens and all types of lymphocytes (1). Dendritic 
cells are critical and previously missing links in 
immune system which are referred to as 
‘professional APCs” due to their principal function 
of presenting antigens and inducing a primary 
response in naïve T lymphocytes (2). This group of 
cells is heterogeneous in terms of cell-surface 
markers, anatomic location, and function. As 
sentinels, dendritic cells patrol the body seeking out 
foreign invaders, no matter these are bacteria 
viruses, tumor antigens or dangerous toxins. New 
research shows that dendritic cells are also 
responsible for a seemingly opposite role in health 
Immunity is controlled by a network of professional antigen presenting cells 
(APCs), the most important of which are known as dendritic cells (DC). Dendritic 
cells are professional APCs that are designed to activate T cells toward various 
antigens, such as tumor-associated antigens, due to their potent co-stimulatory 
activity. They play a crucial role of constantly sampling the microenvironment for 
‘danger signals’, which include inflammatory signals and pathogens. The 
availability of large numbers of DC, generated either from hematopoietic 
progenitor cells or monocytes, holds great promise in the development of cancer 
immunotherapy as well as the treatment of autoimmune diseases and suppressing 
several viruses. Accordingly, appropriately pulsed or transfected DC may be used 
for vaccination in the field of infectious diseases or tumor immunotherapy to 
induce antigen-specific T cell responses. Unlike infectious pathogens, tumors do 
not induce an effective inflammatory response suitable for optimal activation of 
DCs, and as a result the immune response is weak and ineffective. The primary 
purpose of vaccinating individuals with cancer is to overcome this flaw by 
channeling tumor antigens into DCs and providing the conditions for their optimal 
maturation into potent immunostimulatory APCs. This article will focus 
specifically on the use of DCs as vaccines for cancer immunotherapy. We will 
examine DC biology, preclinical and clinical studies and finally efforts to improve 
current vaccine formulations. 
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which silences dangerous immune cells and 
prevents them from attacking materials in the body 
or the body's own tissues which results in auto-
immune diseases (3). 
 
DC morphology and biology 
Dendritic cells are stellate or tree-like cells 
(Greek, dendron, tree) that are found virtually 
everywhere in the body. Being responsible for the 
induction of T or T-dependent immunity and 
tolerance, they are particularly abundant in lymphoid 
or immune organs, and at the interfaces between our 
bodies and the environment such as skin and mucous 
membrane which are the ideal locations to encounter 
invading pathogens (4). Several morphological 
characteristics provide DCs with a variety of 
features to generate an immune response. Dendritic 
cells are so called because of the presence of 
numerous membranous processes that resemble the 
dendrites of neurons. The processes of dendritic cells 
continually form, bend, and retract, hence 
lymphocytes can bind to dendritic cells in large 
numbers. The tentacular shape and constant 
movement of dendritic cells along with the 
intracellular structures relating to antigen processing 
including endosomes and lysosomes, fit precisely 
with their functions (5). 
 
Discovery of dendritic cells 
During the 1970s, most immunologists considered 
macrophages to be the principal antigen presenting 
cells in the immune system. They also believed that 
a group of “accessory cells” which were first thought 
to be a type of macrophages are responsible for the 
process of response initiation. But the uncertainty of 
their identity and function were left behind until 
1973 when Ralph Steinman and the late Zanvil A. 
Cohn first described dendritic cells (5). They found a 
population of striking dendritic-shaped cells in 
mouse spleen. When Steinman evaluated this 
population of cells, obvious resemblance to the well-
known macrophages such as great number of 
membrane enzyme and digestive bodies or 
lysosomes and Fc receptors was not seen. The cells 
had poor viability and rapid turnover in contrast to 
macrophages and showed poor phagocytosis in vivo 
and in vitro (6). Eventually the researches of 
Steinman and Cohn led to the novel discovery of 
dendritic cells and their distinct properties and 
features. The term "accessory" has since been 
replaced by the terms "professional" and "co-
stimulatory," but the basic concept is unchanged as 
dendritic cells provide the T cells with needed 
accessory or co-stimulatory substances, as well as 
giving them a signal to begin to grow and function. 
By 1979 Steinman succeeded to increase the number 
of dendritic cells with a high percent of purity so that 
it was possible to carry out functional studies (7).  
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Further studies revealed their vital stimulatory 
function since dendritic cells were mostly detected 
in T-cell rich lymphatic organs which is the most 
suitable location to initiate immunity (8-10). Subsets 
of dendritic cells with unique surface markers were 
also detected in epithelial organs of animals as well 
as in human blood. The origination of dendritic cells 
and their development through a pathway shared 
with macrophages and granulocytes were also 
discussed. By 1992, Steinman used DC progenitors 
to generate a large number of dendritic cells to 
expand cellular and molecular research on DCs (6). 
 
 Dendritic Cells Generation and Function  
Currently there are two known major subsets of 
dendritic cells in humans: Firstly lymphoid dendritic 
cells derived from plasmacytoid cells in blood, and 
myeloid dendritic cells, the second group arise from 
myeloid precursor cells e.g., peripheral blood 
monocytes or CD34+ progenitors from bone marrow 
(11). In humans, myeloid lineage are considered the 
“classical” DC. Alternatively DCs can be generated 
by culturing CD34+ cells in the presence of various 
appropriate cytokines. One approach which has been 
taken involves depleting the CD34+ cells of 
differentiated precursors and then culturing the cells 
in the presence of GM-CSF and IL-4 ± TNF-α. 
CD34+ cells can be obtained from bone marrow, 
cord blood or G-CSF mobilized peripheral blood. 
Another approach is to generate DC-like cells by 
culturing CD14+ monocyte-enriched PBMC. In the 
presence of GM-CSF and IL-4, there cultures give 
rise to large numbers of DC like cells. These 
monocyte-derived DCs need additional conditioning 
in vitro with either TNF-α or monocyte-conditioned 
media to be able to fully function as a DC capable of 
priming antigen-specific T cell response. A novel 
approach to expand DCs in vivo is presented in a 
review by Fong and Engleman. They saw an 
increase in circulating DCs by 10-3- fold in a 
clinical protocol using Flt3-ligand. These cells could 
be harvested with a leukapheresis procedure and 
used for later immunotherapy. Other molecules may 
also prove useful for the in vivo expansion and 
mobilization of DCs (12). Monocyte-derived DCs 
generated in vitro are phenotypically and 
functionally similar to DCs present in blood. The 
important point is that they can be generated in 
significant numbers, which is a necessity for clinical 
studies. In vitro generation of dendritic cells has 
facilitated clinical vaccine studies using DCs pulsed 
with antigen; which can be formulated as peptides, 
proteins, cell lysates, apoptotic tumor cells, DNA 
and RNA. Dendritic cells develop further or mature 
as they capture, process antigens, and migrate under 
the influence of other chemical messengers to tissues 
such as spleen and lymph nodes. There they attract 
and stimulate T and B cells to produce strong 
immune responses. Dendritic cells as professional 
APCs, are specialized to uptake antigens and convert 
them into MHC-peptide complexes recognized by 
lymphocytes thanks to their receptors. However, 
dendritic cells are capable of doing more than 
presenting antigens to T cells. The function of DCs 
is divided into three main categories, each of which 
include antigen presentation. The first category of 
DC function is antigen presentation and activation of 
T cells. DCs process and present antigen to activate 
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both CD4+ and CD8+ T cells. Only DCs are capable 
of activating naïve T cells hence, this appears to be 
the most crucial role for DCs. Immature DCs 
originate in the bone marrow and migrate throughout 
the body, Once the immature DCs interact with 
invading pathogens or other foreign bodies they 
carry out the primary function of capturing the 
antigens. When exogenous and endogenous antigens 
are captured, they can be processed by DCs and 
presented in the context of either major 
histocompatibility complex (MHC) class I or II 
molecules. For MHC class I presentation to 
stimulate CD8+ cytotoxic T cells through endosomal 
pathway, the antigen or protein is taken up by 
phagocytosis or receptor mediated endocytosis into 
the cytosol. The antigens are further degraded in the 
cytosol via proteasome and enter the endoplasmic 
reticulum where peptides bind to lately synthesized 
MHC class I molecules to be presented on the cell 
surface. For MHC class II presentation through 
proteosomal pathway to stimulate CD4+ T helper 
cells, antigen is taken up by phagocytosis or receptor
-mediated endocytosis to endosomes where some 
proteolysis happens (13,14). The peptides enter a 
vesicle containing MHC class II where they bind and 
are transported to the cell surface. DCs also maintain 
costimulatory molecules on their cell surface 
including members of the B7 family, TNF family 
and intracellular adhesion molecules which are vital 
to the activation of T. The second category of DC 
function is not as well established, but it has been 
suggested that a different class of DCs exist with the 
function of inducing and maintaining immune 
tolerance.(15-19) Dendritic cells not only activate T 
lymphocytes, but also tolerize T cells to antigens 
that are innate to the body (self-antigens), thereby 
minimizing autoimmune reactions. Tolerance is the 
inability of the immune system to respond to specific 
antigens. Central tolerance occurs in the thymus for 
T cells and the bone marrow for B cells. T cells that 
respond to DCs carrying self-peptide are destroyed 
in the thymus by negative selection, preventing the 
occurrence of autoimmune diseases. The third 
category of DCs, known as follicular DCs, appear to 
work to maintain immune memory with the help of 
B lymphocytes. DCs produce a number of cytokines 
and factors which are critical to the activation and 
differentiation of B cells. The follicular DCs appear 
to be important in the maintenance of B cell memory 
(20).  
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DC-based vaccines 
Development of practical procedures to prepare 
sufficient numbers of functional DCs in culture from 
the peripheral blood precursors, paved the way for 
clinical trials to evaluate various DC-based strategies 
in patients with malignant diseases. Vaccination 
strategies involving DCs as the most potent antigen-
presenting cells have been developed owing to the 
special properties of these cells in initiation and 
maintenance of innate and adaptive immune 
responses. By contributing to the generation and 
proliferation of tumor-specific cytotoxic T 
lymphocytes and helper T cells, DC play a critical 
role in the induction of protective and therapeutic 
anti-tumor immunity with tumor antigen-loaded DC 
have been reported in murine tumor models and in 
trials in tumor-bearing patients. The aim of DC 
vaccination is to induce tumor-specific effector T 
cells that can reduce the tumor mass specifically and 
that can induce immunological memory to control 
tumor relapse. In this process, the first step is to 
provide DCs with tumor-specific antigens. This can 
be achieved either by culturing ex vivo DCs that 
have been derived from patients with an adjuvant 
and the tumor-specific antigen, and then injecting 
these cells back into the patient, or by inducing DCs 
to take up the tumor-specific antigen in vivo.  
 
The goal of cancer vaccinologists is to elicit tumor-
specific CD8+ T cell-mediated immune responses 
that will be sufficiently robust and long-lasting to 
generate durable tumor regression and/or 
eradication. This goal is encouraged by clinical 
studies showing that the infusion of autologous 
tumor-specific CD8+ T cells can eventually lead to 
the rejection of large metastatic tumors in patients
(21-23). The aim is to identify vaccination protocols 
that will result in the generation of potent T cell 
responses in vivo. Ideally, vaccine-elicited CD8+ T 
cells should be of high avidity and able to recognize 
peptide–MHC class I complexes on tumor cells; be 
able to express high levels of granzyme and perforin 
— molecules that are essential for cytotoxic activity 
against cancer cells; be able to enter the tumor 
microenvironment; and be able to overcome 
immunomodulatory mechanisms that are present in 
the tumor (24-26). At least four components of the 
immune response are necessary for this ideal 
response to happen: the presence of appropriate 
DCs; the quality of induced CD4+ T helper cells; the 
elimination and/or non-activation of TReg cells; and 
the breakdown of the immunosuppressive tumor 
microenvironment (27).  
www.thecancerpress.com 
Alizadeh, 2017. The Cancer Press, 3(1): 6-12                                                                                                                                           10 
Vol. 3, No.1, March, 2017 
Optimization of the treatment parameters, including 
the DC source, DC maturation, choice of antigens, 
Ag-loading methods, sires of injection, doing, and 
appropriate anti-tumor immunological monitoring, 
will be required to further improve the efficacy of 
this approach. 
 
General approaches 
There are two general approaches for preparing and 
loading tumor antigens. One uses a single tumor-
associated Ag for the induction of a single antigen-
specific monoclonal CTL, and the other uses whole 
tumor cells or their derivatives for the induction of 
multiple antigen-specific polyclonal CTLs. 
Variations in the former approach include the use of 
DCs pulsed with MHC class I-restricted tumor Ag-
derived peptides. Check the ref 10-11. DCs 
transfected with cDNA encoding a particular tumor-
associated Ag (28) and tumor-peptide pulsed DC-
derived exosomes (29). Although clinical trials using 
peptide-pulsed DCs have demonstrated 
immunological and clinical responses in cancers 
such as malignant melanoma (25,30) and prostate 
cancer (24) the application of specific peptides is 
limited to patients who express class I MHCs 
restricted to peptides associated with those tumors. 
Peptide-based immunotherapies also fail to utilize 
MHC class II and CD40L-mediated CD4+ T cell 
helper responses. Various methods have been 
reported for generating DC-based vaccines using 
whole tumor cells or their derivatives including DCs 
pulsed with tumor-associated native or recombinant 
proteins or DCs transfected with whole tumor cell-
derived RNA (3). In clinical trials, some 
investigators reported the efficacy of DCs pulsed 
with whole tumor lysates (13, 25) or stressed tumor 
cells (necrotic or apoptotic) (7, 26), which are more 
practical to obtain than isolated proteins or RNA. 
DC-tumor cell fusion hybrids (DC/TC hybrids) have 
been shown to demonstrate superior efficacy for the 
treatment of murine tumor models (14,15) It is 
important that the hybrids express multiple tumor 
antigens in the context of MHC class I and/or class 
II molecules as well as co-stimulatory molecules 
essential for T-cell activation. Moreover DC/TC 
hybrids have been shown to be efficacious for the 
treatment of both melanoma and renal cell 
carcinoma in Phase I/II clinical trials (31). Strict 
comparative analysis that optimize methods for Ag-
loading whole tumor cells or their derivatives have 
been conducted for melanoma, thymoma or acute 
myeloid leukemia (32-36). 
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Future Perspective 
Since the first trial of DC vaccines for cancer was 
published in 1996, over 100 clinical studies have 
been reported, but there is little consensus as to the  
 
optimal manufacturing strategy (25) Turnis and 
Rooney (2012) speculate that in the future, DC 
vaccines will not be a sole mode of therapy, but a 
weapon in a complementary arsenal.  
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Conclusion 
Effective therapies may require combinations of genetically modified DCs with additional treatments such as 
modulation of angiogenic pathways, depletion of soluble inhibitors, blockade of regulatory cells or adoptive 
transfer of T cells, themselves genetically modified to resist T-cell-directed tumor immune evasion strategies. 
Many unanswered questions hamper the development of DC-based vaccines, including the source of DC 
preparation and protocols for DC generation, activation and loading with tumor antigens, source of tumor 
antigens and route of vaccine administration and methods of immunomonitoring. Fortunately, in spite of the 
many obstacles, DC vaccines continue to hold promise for cancer therapy. 
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